January
- Exclusive
- Trade deals
The pressure tactics that turned CSL from ‘minnow’ to powerhouse
Previously unreported documents show US trade negotiators tried to bust CSL’s Australian monopoly. Brian McNamee says it spurred the company to global success.
- John Kehoe
October 2024
2024’s most powerful and influential directors revealed
As AGM season gathers pace, the BOSS index of the country’s most powerful and influential directors reveals a new cohort rising through the ranks.
- Patrick Durkin
October 2023
CSL ‘never going to be a dividend stock’ says chairman amid pay outcry
“None of us like the share price dropping,” CSL chairman Brian McNamee has told the AGM.
- Patrick Durkin
June 2023
Genesis of a $5b collapse: Inside Dan Collins’ rise and fall
The recriminations have begun following the collapse of the cancer care giant, once valued at $5 billion. At the centre is the Brisbane boy who made it big.
- Carrie LaFrenz and Jemima Whyte
April 2023
How CSL went from ‘bloated bureaucracy’ to $145b global behemoth
Blood Money | When Brian McNamee took on the top job at Commonwealth Serum Laboratories, the government-run entity was barely worth the land it was built on.
- Yolanda Redrup
February 2023
Why business is shying away from campaigning for the Voice
High-profile directors warn the referendum that is designed to give Indigenous people a voice to parliament is complex and no one knows what it will look like.
- Sally Patten and Patrick Durkin
Boards sound alarm on Labor spending, intervention
Leading directors caution against unfettered government spending and unsustainable debt.
- Patrick Durkin and Sally Patten
December 2022
- Opinion
- Chanticleer
Perreault leaves CSL in good hands
CSL’s second seamless transition in 30 years from one CEO to another internal candidate is a blueprint for other complex, global corporations.
- Tony Boyd
April 2022
Barbarians at the gate or global experts at work?
As KKR and its partners continue their due diligence of bid target Ramsay Health Care, AFR Weekend asks if private equity firms can be good owners of such sensitive and vital assets.
- Carrie LaFrenz, Matthew Cranston and James Thomson
December 2021
CSL puts $16.4b bet on ageing, obesity
CSL has offered $US179.25 cash per share for Vifor Pharma, a Swiss pharmaceutical giant specialising in the growing market for kidney disease and iron deficiency treatments.
- Updated
- Carrie LaFrenz and Jemima Whyte
CSL in talks to buy $10b Swiss-based Vifor Pharma Group
The biotechnology giant is in ‘advanced’ discussions with the company that is now run by one of its former directors.
- Updated
- Carrie LaFrenz and Jemima Whyte
November 2021
GenesisCare seeks equity injection from KKR
Dan Collins, founder and chief executive of GenesisCare, said all the health carer’s markets had been affected by COVID-19, with patient concerns over safety.
- Carrie LaFrenz
October 2021
CSL sues US border protection agency over Mexican citizen ban
Chief executive Paul Perreault flexes his muscle in the fight over the Mexican border closure, which has cut off plasma donors from centres in Texas and Arizona.
- Carrie LaFrenz
September 2021
Top tips for success gleaned from leaders over 21 years of BOSS
Take time to think, learn to read people, document your week and keep learning are among the pieces of advice from Australia’s most successful business leaders.
- Sally Patten
August 2021
CSL expects net profit to drop in ‘transitional’ 2022
The biotech giant says this year will be one on transition as it seeks to recover from lower blood plasma collections.
- Updated
- Carrie LaFrenz
CSL appoints biotech entrepreneur as new director
The biotech appoints Professor Duncan Maskell to the board a day ahead of full year results where investors will be looking for blood plasma collections recovery.
- Carrie LaFrenz
September 2020
- Opinion
- The AFR View
It's time Daniel Andrews owned up to his elimination plan
Daniel Andrews' “aggressive suppression” euphemism is extending false hope to lockdown-fatigued Victorians about life, work, and business being back to normal by Christmas.
- The AFR View
August 2020
McNamee 'stunned' by Andrews' power grab
CSL's chairman said it was 'radically wrong' for the Victorian Premier to extend emergency powers, saying he had not 'earned or deserved' the right to crush people's civil liberties.
- John Kehoe
- Opinion
- The AFR View
Growing cause to question the Andrews strategy
We may still all be Melburnians, but the huge national cost of Victoria's lockdown demands more answers than the country is getting.
- The AFR View
- Exclusive
- Coronavirus pandemic
CSL boss calls for new virus strategy
The chairman of the global biotechnology giant, Brian McNamee, has warned of the far-reaching economic, social and health consequences of Melbourne's lockdown.
- John Kehoe